The starting point

There is a common conflation in how deprescribing is discussed — by patients and by clinicians alike. The risks of unmanaged, abrupt cessation are treated as though they are the same as the risks of a gradual, clinically supervised reduction. They are not.

Almost all of the serious harm associated with stopping psychiatric medication comes from stopping too quickly, without adequate support, or at the wrong point in a person's life. When these factors are properly addressed, deprescribing is a safe process for the majority of people who pursue it.

The relevant question is not whether it can be done safely. The question is what needs to be in place — for this person, with this medication, at this point in time.

What makes deprescribing safe

The following factors substantially reduce the risks associated with psychiatric medication reduction. They are not a checklist to be ticked before starting — they are conditions to be actively created and maintained throughout the process.

✓

Consultant psychiatric oversight throughout The taper is led and monitored by a highly experienced consultant psychiatrist who understands both the pharmacology of the specific medication and the individual's clinical history. This is not a process that can be safely delegated to a protocol or managed remotely without regular clinical contact.

✓

Proportional, hyperbolic dose reductions Reductions are made as a percentage of the current dose — not in fixed milligram amounts. Because the relationship between dose and receptor occupancy is curved rather than linear, equal-step reductions produce increasingly large neurological effects as the dose gets lower. Proportional reductions avoid this. See what is hyperbolic tapering.

✓

Response-led pacing The speed of reduction is determined by how the person is responding — not by a fixed schedule or an end date. When symptoms arise, the pace slows or holds. When the person is stable, the process continues. There is no timeline that takes precedence over the nervous system's actual capacity.

✓

Starting from a stable baseline The person is broadly stable — not in acute psychiatric crisis, not under extreme concurrent life stress. Stability gives the nervous system the spare capacity it needs to navigate medication change. It is one of the strongest predictors of a manageable process.

✓

A framework for interpreting what arises The person understands what withdrawal feels like, how it differs from relapse, and what an appropriate clinical response to symptoms looks like. Fear of symptoms — rather than the symptoms themselves — is often what derails a taper. Knowing what to expect substantially reduces fear-driven decisions at critical moments.

✓

Appropriate formulations at each stage Precise dose reductions at lower doses require liquid preparations — standard tablet strengths are too coarse for the lower stages of most tapers. A safe deprescribing plan accounts for formulation requirements well in advance of reaching them, not as an afterthought.

✓

Inner stability developing alongside medication reduction Psychiatric medication provides chemical stability. As it reduces, the nervous system's own regulatory capacity needs to be present or actively developing. This is not a hard prerequisite — many people begin tapering before they feel fully stable — but its presence meaningfully improves the experience and reduces distress at each stage.

What increases risk

The following conditions do not make deprescribing impossible — but they require greater care, a slower approach, or in some cases a period of delay until circumstances improve. Recognising risk factors early is a core part of responsible clinical planning.

Acute psychiatric instability Active suicidal ideation, acute psychosis, severe depressive episode or acute mania indicate the nervous system does not currently have the capacity to navigate medication change safely. In most cases, deprescribing should be deferred until meaningful stability is restored.

Abrupt or rapid reduction Stopping psychiatric medication suddenly — or reducing in large steps over a short period — is the most common cause of serious withdrawal effects. The nervous system cannot adapt quickly enough. This produces severe, distressing symptoms that are frequently misinterpreted as relapse, leading to premature reinstatement and repeated cycles of destabilisation.

Long duration of use at high dose The longer a person has been on a medication and the higher the dose, the more fully the nervous system has adapted to its presence. More extensive neurological adaptation means a longer, slower taper is required. Treating a ten-year high-dose prescription with the same approach as a three-month low-dose one is a significant risk factor.

Short half-life medications without formulation planning Venlafaxine, paroxetine and duloxetine leave the body quickly — withdrawal can begin within hours of a missed or reduced dose. These medications require liquid formulations for accurate low-dose tapering. Attempting to taper using standard tablet strengths alone is insufficient and significantly increases both the severity and unpredictability of withdrawal at the lower stages.

Significant concurrent life stressors Bereavement, relationship breakdown, job loss, housing instability — significant external pressures reduce nervous system reserve. A taper that would be manageable under stable conditions may be very difficult during a period of high external stress. Sometimes the most clinically sound decision is to wait.

A history of difficult previous reduction attempts Someone who experienced severe withdrawal on a previous attempt almost always experienced a method problem, not a capacity problem. Their nervous system is signalling something important: it responds strongly to dose changes and needs a more gradual, more carefully managed approach than it received before. This history should inform the plan — it should not close the door on the goal.

No clinical support in place Attempting deprescribing without regular access to a clinician who can interpret symptoms, adjust the pace and provide a containing clinical relationship substantially increases the likelihood of distress, fear-driven decisions, and abandonment of the process. This is not something most people can safely navigate alone, regardless of how much they have read.

The risk in deprescribing is almost never the reduction itself. It is the speed, the method, and the absence of appropriate clinical support.

Why method determines outcome

The evidence on deprescribing outcomes is consistent on one point: method is the primary determinant of experience. Where people received gradual, proportional tapering with regular clinical contact, the majority completed the process successfully and without significant distress. Where rapid, fixed reductions were used with minimal support, distress was common and completion rates were low.

This has an important implication for how previous difficult experiences should be interpreted. The clinical response is sometimes "this person cannot tolerate deprescribing." The evidence suggests a different reading: the approach used was not appropriate for this person's nervous system. The right question is not whether someone can reduce, but what method — at what pace, with what level of support — is right for them at this particular time.

What the evidence consistently supports

Gradual, proportional tapering is substantially safer than linear or time-limited reduction
Response-led pacing — adjusting to the individual's nervous system — produces better outcomes than fixed schedules
Regular clinical monitoring reduces fear, improves decision-making and enables timely adjustment
Starting from a position of stability is one of the strongest predictors of a manageable process
Previous difficult experiences almost always reflect the method, not the person's capacity to change
The nervous system has a remarkable capacity to recover — it needs time, appropriate pacing, and clinical support

Risk assessment in practice

Every deprescribing plan we build begins with a thorough assessment of the individual's specific risk profile — a clinical judgement that considers the medication and how long it has been prescribed, the dose, the person's current stability, their previous experiences of dose changes, their life circumstances, and the inner and outer resources available to support the process.

Some people need a very gradual taper over many months or years. Others move more quickly. Both are valid. The goal is not to reach zero by a particular date — it is to move through the process safely and without unnecessary destabilisation at any stage.

Where risk factors are present, the plan is adjusted: greater care, slower pacing, more frequent monitoring. Not avoidance of the goal.

This page is educational

This explainer provides general information about factors affecting deprescribing safety. It does not replace individual clinical assessment. If you are considering reducing or stopping psychiatric medication, please do so with proper clinical support — not alone, and not abruptly.

For GPs and prescribers

Key factors to assess when considering deprescribing for a patient:

Current psychiatric stability — is the patient broadly stable and not in acute crisis?
Duration and dose — longer use at higher doses requires a slower, more carefully managed taper
Medication half-life — venlafaxine, paroxetine and duloxetine require liquid formulations for accurate low-dose reduction
Previous experiences of dose change — significant withdrawal history indicates the nervous system responds strongly and requires a more gradual approach
Current life stressors — major concurrent stressors reduce nervous system reserve and may warrant deferring the taper

We are happy to liaise directly with GPs regarding patients undergoing structured deprescribing and can issue private prescriptions for liquid formulations throughout the taper. No formal referral letter is required.

Deprescribing done properly is not a risk to be managed. It is a process to be respected — one that, given the right conditions, the right pace, and the right clinical support, is within reach for most people who want it.

If you would like to discuss your situation — your medication, your history, and whether now is the right time to explore reduction — an initial consultation is a conversation, not a commitment.

Get in touch →

What makes psychiatric medicationdeprescribing safe — and what increases risk?